MHRA backs gene therapy in battle with ‘bubble baby’ disease – The Pharma Letter (registration)
|
MHRA backs gene therapy in battle with ‘bubble baby’ disease
The Pharma Letter (registration) The UK Medicines and Healthcare Products Regulatory Agency (MHRA) has granted a Promising Innovative Medicine Designation to OTL-101 for the treatment of adenosine deaminase severe combined immunodeficiency, commonly known as ADA-SCID, … |
|
Mass General, CRISPR Therapeutics to Develop Cancer Therapies
GenomeWeb NEW YORK (GenomeWeb) – CRISPR Therapeutics and Massachusetts General Hospital Cancer Center (MGHCC) announced today that they have signed a two-year research collaboration and license option agreement to develop novel T-cell therapies for … |
Press Telegraph |
CRISPR Therapeutics, MGH Partner to Develop T–Cell Cancer Therapies
Genetic Engineering & Biotechnology News CRISPR Therapeutics’ interest in next-generation T–Cell cancer immunotherapies comes as both Kite Pharma and Novartis await FDA decisions on their CAR-T immuno-oncology treatments, with the companies emerging as leading developers of CAR-T … Building up its I/O ops, CRISPR Therapeutics allies with Marcela Maus at Mass GeneralEndpoints News CRISPR Therapeutics Announces Collaboration with Massachusetts General Hospital to Research Use of CRISPR …GlobeNewswire (press release) |
Press Telegraph |
CRISPR Therapeutics, MGH Partner to Develop T–Cell Cancer Therapies
Genetic Engineering & Biotechnology News CRISPR Therapeutics’ interest in next-generation T–Cell cancer immunotherapies comes as both Kite Pharma and Novartis await FDA decisions on their CAR-T immuno-oncology treatments, with the companies emerging as leading developers of CAR-T … Building up its I/O ops, CRISPR Therapeutics allies with Marcela Maus at Mass GeneralEndpoints News CRISPR Therapeutics Announces Collaboration with Massachusetts General Hospital to Research Use of CRISPR …GlobeNewswire (press release) |
Insider Financial |
US Stem Cell Inc (OTCMKTS:USRM): Buy The Science
Insider Financial Regular readers will know that US Stem Cell Inc (OTCMKTS:USRM) is one of the companies we keep coming back to here at Insider Financial. It’s a biotech play that, as outlined in previous coverage, we feel is undervalued at current prices and we think … |
Insider Financial |
US Stem Cell Inc (OTCMKTS:USRM): Buy The Science
Insider Financial Regular readers will know that US Stem Cell Inc (OTCMKTS:USRM) is one of the companies we keep coming back to here at Insider Financial. It’s a biotech play that, as outlined in previous coverage, we feel is undervalued at current prices and we think … |